X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-07-06 | PBYI | Puma Biotechnology, Inc. | Auerbach Alan H | Pres, CEO, 10% | S - Sale | $8.26 | -44,058 | 7,261,671 | -1% | -$364,051 | ||||||
2026-07-06 | PBYI | Puma Biotechnology, Inc. | Hunt Douglas M | See Remarks | S - Sale | $8.26 | -8,460 | 196,841 | -4% | -$69,905 | ||||||
2026-07-06 | PBYI | Puma Biotechnology, Inc. | Nougues Maximo F | CFO | S - Sale | $8.26 | -9,386 | 230,637 | -4% | -$77,557 | ||||||
| M | 2026-07-06 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.48 | +57,210 | 2,698,518 | +2% | +$141,865 | |||||
2026-07-07 | EVMN | Evommune, Inc. | Kirsch Arthur S | Dir | P - Purchase | $13.30 | +10,000 | 10,000 | New | +$133,000 | ||||||
| D | 2026-07-07 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $93.13 | -20,000 | 3,985 | -83% | -$1,862,530 | |||||
| D | 2026-07-08 | CTNM | Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO, Pres | S - Sale+OE | $16.00 | -2,500 | 17,217 | -13% | -$40,000 | |||||
| M | 2026-07-06 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Dir | S - Sale | $22.97 | -777,451 | 2,962 | -100% | -$17,858,492 | |||||
| M | 2026-07-06 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.31 | -143,199 | 0 | -100% | -$44,749 | |||||
| D | 2026-07-06 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $85.08 | -5,079 | 105,272 | -5% | -$432,118 | |||||
| DM | 2026-07-06 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $87.52 | -46,774 | 63,198 | -43% | -$4,093,482 | |||||
2026-07-06 | ELVN | Enliven Therapeutics, Inc. | Kunkel Lori Anne | Dir | S - Sale | $50.49 | -10,000 | 41,884 | -19% | -$504,903 | ||||||
| D | 2026-07-06 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $122.27 | -20,000 | 381,809 | -5% | -$2,445,382 | |||||
2026-07-06 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale | $122.26 | -5,000 | 42,181 | -11% | -$611,273 | ||||||
| D | 2026-07-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $558.87 | -9,500 | 668,728 | -1% | -$5,309,296 | |||||
| D | 2026-07-06 | ALMS | Alumis Inc. | Pangali Sanam | GC | S - Sale+OE | $28.00 | -5,000 | 11,111 | -31% | -$140,000 | |||||
2026-07-06 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $12.00 | -300 | 254,572 | 0% | -$3,600 | ||||||
| D | 2026-07-06 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $123.72 | -30,000 | 324,879 | -8% | -$3,711,600 | |||||
| M | 2026-07-06 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $80.68 | -75,000 | 851,667 | -8% | -$6,051,170 | |||||
| M | 2026-07-06 | TBPH | Theravance Biopharma, Inc. | Samaha Eli | 10% | S - Sale | $17.14 | -6,964 | 9,167,489 | 0% | -$119,397 | |||||
2026-07-06 | LRMR | Larimar Therapeutics, Inc. | Hamilton Thomas Edward | Dir | P - Purchase | $3.34 | +50,000 | 874,231 | +6% | +$166,890 | ||||||
| D | 2026-07-06 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $109.98 | -12,302 | 60,486 | -17% | -$1,352,932 | |||||
2026-07-07 | PRQR | Proqr Therapeutics N.V. | De Boer Daniel Anton | CEO | P - Purchase | $1.59 | +150,000 | 150,000 | New | +$238,500 | ||||||
| M | 2026-07-06 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Pres, CFO | S - Sale | $36.12 | -4,800 | 84,040 | -5% | -$173,375 | |||||
| D | 2026-07-06 | DMRA | Damora Therapeutics, Inc. | Winslow Garrett | GC | S - Sale+OE | $29.98 | -245 | 2,289 | -10% | -$7,345 | |||||
| D | 2026-07-06 | NBP | Novabridge Biosciences | Xu Cong Claire | SVP, Clinical Development | S - Sale+OE | $0.89 | -4,485 | 298,101 | -1% | -$3,992 | |||||
| M | 2026-07-06 | IMNM | Immunome Inc. | Barchas Isaac | Dir | S - Sale | $24.13 | -100,000 | 211,763 | -32% | -$2,412,522 | |||||
| D | 2026-07-02 | STTK | Shattuck Labs, Inc. | Shukla Abhinav A. | Chief Technical Officer | S - Sale+OE | $7.01 | -410 | 98,533 | 0% | -$2,874 | |||||
| M | 2026-07-02 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% | S - Sale | $37.64 | -126,685 | 2,733,315 | -4% | -$4,768,637 | |||||
| M | 2026-07-02 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $14.02 | -110,023 | 146,305 | -43% | -$1,542,970 | |||||
| D | 2026-07-02 | IMNM | Immunome Inc. | Lechleider Robert | Chief Medical Officer | S - Sale+OE | $22.62 | -55,000 | 15,805 | -78% | -$1,244,331 | |||||
| M | 2026-07-06 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | See Remarks | S - Sale | $8.52 | -45,000 | 1,366,053 | -3% | -$383,176 | |||||
| D | 2026-07-07 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $86.62 | -3,500 | 153,902 | -2% | -$303,170 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Perry Jennifer Scott | COO | S - Sale | $4.29 | -1,412 | 91,052 | -2% | -$6,054 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Skynner Michael | CHIEF SCIENTIFIC OFFICER | S - Sale | $4.28 | -2,391 | 157,171 | -1% | -$10,231 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Lee Kevin | CEO | S - Sale | $4.28 | -7,642 | 603,671 | -1% | -$32,701 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale | $4.28 | -1,761 | 94,375 | -2% | -$7,530 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Thompson Travis Alvin | CFO | S - Sale | $4.27 | -923 | 64,441 | -1% | -$3,945 | |||||
2026-07-06 | IMNN | Imunon, Inc. | Eylward Susan | GC, Corp Sec | S - Sale | $1.88 | -920 | 2,896 | -24% | -$1,730 | ||||||
| D | 2026-07-02 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, MD | S - Sale+OE | $45.16 | -21,082 | 519,227 | -4% | -$952,051 | |||||
| D | 2026-07-06 | SION | Sionna Therapeutics, Inc. | Fitzpatrick Jennifer | GC | S - Sale+OE | $43.60 | -10,250 | 0 | -100% | -$446,862 | |||||
2026-07-02 | CRNX | Crinetics Pharmaceuticals, Inc. | Vivaldi Coelho Rogerio | Dir | S - Sale | $40.00 | -3,000 | 19,225 | -13% | -$120,000 | ||||||
2026-07-02 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | P - Purchase | $3.54 | +7,851 | 81,385 | +11% | +$27,793 | ||||||
2026-07-06 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | S - Sale | $3.51 | -9,022 | 81,385 | -10% | -$31,667 | ||||||
2026-07-02 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $524.99 | -1,500 | 45,321 | -3% | -$787,485 | ||||||
2026-07-02 | VRTX | Vertex Pharmaceuticals Inc / Ma | McKechnie Duncan | EVP, Chief Commercial Officer | S - Sale | $519.00 | -1,541 | 11,001 | -12% | -$799,779 | ||||||
2026-07-02 | REGN | Regeneron Pharmaceuticals, Inc. | Ryan Arthur F | Dir | S - Sale | $650.15 | -200 | 17,303 | -1% | -$130,030 | ||||||
| D | 2026-07-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $548.96 | -9,500 | 668,728 | -1% | -$5,215,133 | |||||
| D | 2026-07-02 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale+OE | $86.00 | -3,313 | 177,543 | -2% | -$284,918 | |||||
| D | 2026-07-01 | IONS | Ionis Pharmaceuticals Inc | Klein Joseph III | Dir | S - Sale+OE | $79.04 | -11,518 | 11,214 | -51% | -$910,416 | |||||
2026-07-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $240.47 | -6,000 | 366,682 | -2% | -$1,442,820 | ||||||
| D | 2026-07-01 | BOLD | Boundless Bio, Inc. | Crandell Keith | 10% | S - Sale+OE | $2.49 | -16,000 | 2,694,095 | -1% | -$39,840 | |||||
2026-07-01 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $79.47 | -25,000 | 926,667 | -3% | -$1,986,695 | ||||||
| D | 2026-07-01 | BOLD | Boundless Bio, Inc. | Arch Venture Fund Ix, L.P. | 10% | S - Sale+OE | $2.49 | -16,000 | 2,694,095 | -1% | -$39,840 | |||||
| D | 2026-07-01 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale+OE | $313.28 | -5,000 | 41,514 | -11% | -$1,566,377 | |||||
2026-07-06 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $54.03 | -2,034 | 227,490 | -1% | -$109,897 | ||||||
| D | 2026-07-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $88.35 | -25,000 | 119,472 | -17% | -$2,208,737 | |||||
| D | 2026-07-01 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $123.59 | -23,000 | 58,117 | -28% | -$2,842,570 | |||||
| D | 2026-07-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $123.58 | -11,430 | 85,533 | -12% | -$1,412,519 | |||||
2026-07-01 | ALXO | Alx Oncology Holdings Inc | Wong Shelly | SVP, FINANCE, CAO | S - Sale | $2.04 | -1,404 | 88,401 | -2% | -$2,864 | ||||||
2026-07-01 | ZLAB | Zai Lab Ltd | Gaynor Richard | Dir | P - Purchase | $19.05 | +1,736 | 80,737 | +2% | +$33,071 | ||||||
2026-07-01 | VRTX | Vertex Pharmaceuticals Inc / Ma | Liu Joy | EVP, GC | S - Sale | $502.71 | -828 | 19,131 | -4% | -$416,244 | ||||||
2026-07-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $32.66 | -7,228 | 27,598 | -21% | -$236,068 | ||||||
2026-07-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $33.13 | -4,698 | 100,991 | -4% | -$155,645 | ||||||
| D | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $87.74 | -7,500 | 97,994 | -7% | -$658,040 | |||||
| D | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | S - Sale+OE | $87.70 | -8,334 | 0 | -100% | -$730,896 | |||||
2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $87.69 | -15,000 | 582,540 | -3% | -$1,315,346 | ||||||
| M | 2026-06-30 | IMNM | Immunome Inc. | Barchas Isaac | Dir | S - Sale | $21.85 | -201,050 | 620,267 | -24% | -$4,393,024 | |||||
| DM | 2026-06-30 | STTK | Shattuck Labs, Inc. | Shukla Abhinav A. | Chief Technical Officer | S - Sale+OE | $7.08 | -23,465 | 86,380 | -21% | -$166,131 | |||||
2026-06-30 | STTK | Shattuck Labs, Inc. | Pandite Arundathy N. | Chief Medical Officer | S - Sale | $7.01 | -30,000 | 136,219 | -18% | -$210,300 | ||||||
| M | 2026-06-30 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.50 | +107,463 | 2,641,308 | +4% | +$268,880 | |||||
| D | 2026-07-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $29.59 | -27,000 | 115,743 | -19% | -$798,908 | |||||
2026-06-30 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $70.00 | -5,681 | 9,756 | -37% | -$397,670 | ||||||
| D | 2026-06-30 | ROIV | Roivant Sciences Ltd. | Fitzgerald Meghan | Dir | S - Sale+OE | $34.90 | -10,000 | 42,963 | -19% | -$349,000 | |||||
| M | 2026-06-30 | INM | Inmed Pharmaceuticals Inc. | Vivo Opportunity, LLC | 10% | P - Purchase | $1.55 | +6,551 | 797,530 | +1% | +$10,148 | |||||
| D | 2026-07-01 | SEPN | Septerna, Inc. | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $34.36 | -3,333 | 96,412 | -3% | -$114,528 | |||||
| M | 2026-07-01 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Pres, CFO | S - Sale | $34.71 | -4,800 | 88,840 | -5% | -$166,586 | |||||
| M | 2026-07-01 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $71.97 | +1,712 | 506,712 | 0% | +$123,220 | |||||
| D | 2026-07-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $23.56 | -11,008 | 13,579 | -45% | -$259,366 | |||||
2026-07-01 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale | $120.00 | -2,721 | 3,114 | -47% | -$326,520 | ||||||
| D | 2026-07-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $554.61 | -9,500 | 668,728 | -1% | -$5,268,781 | |||||
| DM | 2026-06-30 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale+OE | $15.99 | -37,179 | 145,312 | -20% | -$594,578 | |||||
| D | 2026-07-01 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $39.41 | -200,000 | 24,555 | -89% | -$7,881,402 | |||||
2026-07-01 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $84.92 | -7,500 | 381,996 | -2% | -$636,900 | ||||||
| D | 2026-07-01 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $85.80 | -15,000 | 58,555 | -20% | -$1,287,000 | |||||
| D | 2026-07-01 | CYTK | Cytokinetics Inc | Lee Sung | EVP, CFO | S - Sale+OE | $87.79 | -1,112 | 63,221 | -2% | -$97,622 | |||||
| D | 2026-07-01 | ORMP | Oramed Pharmaceuticals Inc. | Hexter Joshua | COO, CBO | S - Sale+OE | $4.46 | -137,000 | 1,073,384 | -11% | -$611,431 | |||||
2026-07-01 | ORMP | Oramed Pharmaceuticals Inc. | Gabay Avraham | CFO | S - Sale | $4.51 | -73,360 | 671,785 | -10% | -$330,744 | ||||||
| D | 2026-06-30 | QURE | Uniqure N.V. | Abi-Saab Walid | Chief Medical Officer | S - Sale+OE | $46.42 | -30,000 | 148,235 | -17% | -$1,392,600 | |||||
| D | 2026-06-30 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale+OE | $46.44 | -21,167 | 25,996 | -45% | -$983,030 | |||||
2026-06-30 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $45.50 | -115,844 | 2,555,877 | -4% | -$5,270,902 | ||||||
2026-06-30 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $45.50 | -115,844 | 2,555,877 | -4% | -$5,270,902 | ||||||
2026-07-01 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $8.03 | -90,000 | 1,716,126 | -5% | -$722,511 | ||||||
2026-07-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $8.03 | -16,666 | 1,161,128 | -1% | -$133,860 | ||||||
2026-07-01 | GNLX | Genelux Corp | Smither John W | Dir | S - Sale | $2.91 | -12,000 | 91,403 | -12% | -$34,898 | ||||||
| D | 2026-07-02 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $552.56 | -8,300 | 45,172 | -16% | -$4,586,275 | |||||
| D | 2026-07-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $543.66 | -9,500 | 668,728 | -1% | -$5,164,789 | |||||
2026-06-30 | ABEO | Abeona Therapeutics Inc. | Alland Leila | Dir | S - Sale | $5.92 | -11,000 | 162,614 | -6% | -$65,087 | ||||||
2026-07-01 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $55.88 | -9,099 | 19,020 | -32% | -$508,454 | ||||||
2026-07-01 | MLTX | Moonlake Immunotherapeutics | Santos Da Silva Jorge | CEO | S - Sale | $20.03 | -47,775 | 2,877,118 | -2% | -$956,933 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |